Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010:2010:497429.
doi: 10.1155/2010/497429. Epub 2009 Dec 24.

Treatment for recurrent ovarian cancer-at first relapse

Kimio Ushijima  1
Affiliations

Treatment for recurrent ovarian cancer-at first relapse

Kimio Ushijima. J Oncol. 2010.

Abstract

Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although most patients receive standardized surgery and chemotherapy, the status of recurrent disease is heterogeneous. The site of recurrence and the survival intervals after recurrence are also widely distributed. Among a number of factors, many clinical trials identified time to recurrence was the factor most related to chemosensitivity at first relapse. The current recommendation for platinum sensitive ovarian cancer is a carboplatin containing combination chemotherapy. Generally, a single agent is chosen for platinum resistant ovarian cancer. Patients with single site recurrence and a long disease free interval are candidates for secondary cytoreduction, which may provide longer survival. There are several treatment choices at first relapse, and disease status, chemotherapy-free interval, and the patient's condition play a major role in the decision making process.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Treatment free intervals and platinum sensitivity.
See this image and copyright information in PMC

References

    1. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clinical Cancer Research. 2004;10(22):7439–7449. - PubMed
    1. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. Journal of Clinical Oncology. 1998;16(4):1494–1497. - PubMed
    1. du Bois A, Lück HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer—a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group. Annals of Oncology. 2001;12(8):1115–1120. - PubMed
    1. Power P, Stuart G, Oza A, et al. Efficacy of pegylated liposomal doxorubicin (PLD) plus carboplatin in ovarian cancer patients who recur within six to twelve months: a phase II study. Gynecologic Oncology. 2009;114(3):410–414. - PubMed
    1. Ushijima K, Hirakawa T, Saitoh T, et al. Phase II study of docetaxel and carboplatin in patients with recurrent epithelial ovarian cancer after first-line treatment with paclitaxel and/or platinum treatment. In: Proceedings of the 10th IGCS Biennial Meeting; October 2004; Edinburgh, UK. abstract no. #469.

LinkOut - more resources